Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...
Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
Purpose: The pharmacology, pharmacokinetics, efficacy, safety, drug interactions, dosage and administration, cost, and place in therapy of duloxetine for major depression, pain from diabetic ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with ...
Artelo Biosciences Inc.’s IND application for ART-26.12, for the treatment of chemotherapy-induced peripheral neuropathy, has been granted clearance by the FDA allowing the company to initiate a first ...
Dr. Shirley D'Sa discusses the importance of catching peripheral neuropathy in patients with Waldenström macroglobulinemia early on and how to treat it. Waldenström macroglobulinemia (WM) is a type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback